Variations of serum IgG subclass levels in hepatitis C virus infection during interferon-α therapy

Musset, Lucile; Ghillani, Pascale; Lunel, F.; Cacoub, Patrice; Cresta, Pascale; Frangeul, Lionel; Rosenheim, M.; Preud’homme, Jean-Louis

doi:10.1016/s0165-2478(96)02681-8

Cited by 5 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand a significant increase was observed in (G. IV-G. VI) as compared to HCV-non treated group (G. II). The obtained data are nearly similar to Musset et al (1997) they stated that a significant decrease in IgGl levels was observed after 6 months of therapy. Posttherapy decrease in serum IgGl levels was observed in eight of the 11 patients who had high serum IgGl prior to treatment and in two of four patients with initially normal IgGl levels.…”

Section: Discussionsupporting

confidence: 88%

“…this might suggest that IFN-α (therapy mainly normalized abnormally high IgGl levels rather than normal values. IFN-α might modify serum IgG levels by affecting their production either directly or through a cytokine cascade than indirectly by its effect on the viral infection (Musset et al, 1997). Moreover the biologic effects of various lFN are quite heterogenous and IFN has been shown to inhibit cell growth, to activate natural killer cells and to affect leukocyte migration.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Biochemical evaluation of the combination of Pegylated IFN-α2b and Ribavarin therapy of Egyptian patients suffering from Hepatitis C Virus

Hussein

Senosi

Barky

et al. 2017

Benha Veterinary Medical Journal

View full text Add to dashboard Cite

The purpose of this study was to evaluate the biochemical parameters and cytokines levels in infected Egyptian patient. This study was conducted on 32 patients. 25 of them were suffering from chronic HCV and the other 7 males are selfreported healthy volunteers. They were classified as the following: Group I (control healthy group), Group II (HCV-non treated group) Group III-Group VI (HCV-treated with 12,24,36,48 ampoule of interferon). The obtained results showed a significant increase in the activities of serum liver marker enzymes ALT, AST and ALP, cytokines Il2, Il4 and Il10, also a significant increase was observed in serum Ferritin and Alpha feto protein. On the other hand, a significant decrease in both sera total protein and albumin level. Whereas administration of combination of Pegylated IFN-α2b and Ribavarin significantly improved the alert in the biochemical parameters. These results suggested that, combination therapy of both peg-interferon and ribavirin, emphasizing the influence of these compounds for patient with HCV, possibly preventing alteration of enzymes of liver activities. Because peg-interferon treatment can reduce liver injury and anti-inflammatory effect, as well as by decreasing plasma cytokine as cytokines, is present in patients with HCV liver disease. Furthermore, treatment with IFN-α diminishes the Th2 cytokine response. Thus, modulation of T-cell function and cytokine production may be one mechanism whereby IFN-α therapy results in reduced viral burden.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Biochemical evaluation of the combination of Pegylated IFN-α2b and Ribavarin therapy of Egyptian patients suffering from Hepatitis C Virus

Hussein

Senosi

Barky

et al. 2017

Benha Veterinary Medical Journal

View full text Add to dashboard Cite

show abstract

“…The accumulation supports that the pathogenic role of CIC in liver injury might be present, but more data, including studies in liver biopsies, are necessary to confirm the role. We have confirmed the results, showing increased Ig and decreased C3 in HCV‐infected patients in this study [23–26]. The low serum C3 may result from liver injury, because the liver is the main organ of C3 synthesis, while the high serum Igs may be related to the fact that the liver plays a role in the regulation of Ig synthesis.…”

Section: Discussionsupporting

confidence: 88%

C3/Ig and Ig/C3 two-component-determined circulating immune complexes (TCIC) in patients with HCV infection

Wang

Yang

Zhang

et al. 2003

FEMS Immunology &Amp; Medical Microbiology

View full text Add to dashboard Cite

In the present study, we measured the levels of immunoglobulin (Ig)- and complement 3 (C3)-determined circulating immune complexes (two-component-determined CIC, or TCIC) in hepatitis C virus (HCV)-infected patients. TCIC was dissected into C3/Ig-TCIC and Ig/C3-TCIC by a reciprocal use of coating and detecting antibodies. The current study was carried out in 117 infected HCV patients and 252 healthy controls. We found that C3/Ig-TCIC elevation was a common feature in patients with HCV infection. Positive rates and levels of C3/IgG-TCIC and C3/IgM-TCIC were significantly higher in the patients with abnormal alanine aminotransferase (ALT) than patients with normal ALT (70.6% vs. 17.0%, 0.56 OD vs. 0.47 OD and 0.71 OD vs. 0.65 OD, respectively, P<0.001). However, the levels of IgM/C3-TCIC and IgA/C3-TCIC were significantly higher in individuals with HCV infection than in healthy controls, whereas the level of IgG/C3-TCIC was significantly lower in the former group than in the latter group. In summary, our results suggest that IgG and C3 TCIC may play an important role in liver cell injury during the course of HCV infection and may be a hallmark for hepatitis C pathogenesis. Elevated C3/Ig-TCIC, accompanied by decreased Ig/C3-TCIC, forms a peculiar trait in HCV infection. Our findings thus provide new insights into HCV pathogenesis.

show abstract

“…The intragenotypic chimera 2B.1.1/JFH1 and the intergenotypic chimera gt1a H77/JFH1 (HQL) have been described previously (20,30). For neutralization assays, HCVpp and purified patient IgG at 100 g/ml (equivalent to a serum dilution of 1:100 to 1:250 on the basis of the known IgG levels in sera from patients with chronic HCV [37]) were mixed, and the mixture was incubated for 1 h at 37°C and then used to infect Huh7 cells for 4 h. The inoculum was removed, and fresh medium was added. Cells were lysed at 3 days postinfection, and infectivity was assessed using a GloLysis luciferase assay (Promega).…”

Section: Methodsmentioning

confidence: 99%

Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection

Swann

Cowton

Robinson

et al. 2016

J Virol

View full text Add to dashboard Cite

During hepatitis C virus (HCV) infection, broadly neutralizing antibody (bNAb) responses targeting E1E2 envelope glycopro-teins are generated in many individuals. It is unclear if these antibodies play a protective or a pathogenic role during chronic infection. In this study, we investigated whether bNAb responses in individuals with chronic infection were associated with differences in clinical presentation. Patient-derived purified serum IgG was used to assess the breadth of HCV E1E2 binding and the neutralization activity of HCV pseudoparticles. The binding and neutralization activity results for two panels bearing viral envelope proteins representing either an intergenotype or an intragenotype 1 group were compared. We found that the HCV load was negatively associated with strong cross-genotypic E1E2 binding (P ‫؍‬ 0.03). Overall, we observed only a modest correlation between total E1E2 binding and neutralization ability. The breadth of intergenotype neutralization did not correlate with any clinical parameters; however, analysis of individuals with genotype 1 (gt1) HCV infection (n ‫؍‬ 20), using an intragenotype pseudoparticle panel, found a strong association between neutralization breadth and reduced liver fibrosis (P ‫؍‬ 0.006). A broad bNAb response in our cohort with chronic infection was associated with a single nucleotide polymorphism (SNP) in the HLA-DQB1 gene (P ‫؍‬ 0.038), as previously reported in a cohort with acute disease. Furthermore, the bNAbs in these individuals targeted more than one region of E2-neutralizing epitopes, as assessed through cross-competition of patient bNAbs with well-characterized E2 antibodies. We conclude that the bNAb responses in patients with chronic gt1 infection are associated with lower rates of fibrosis and host genetics may play a role in the ability to raise such responses. IMPORTANCEGlobally, there are 130 million to 150 million people with chronic HCV infection. Typically, the disease is progressive and is a major cause of severe liver cirrhosis and hepatocellular carcinoma. While it is known that neutralizing antibodies have a role in spontaneous clearance during acute infection, little is known about their role in chronic infection. In the present work, we investigated the antibody response in a cohort of chronically infected individuals and found that a broadly neutralizing antibody response is protective and is associated with reduced levels of liver fibrosis and cirrhosis. We also found an association between SNPs in class II HLA genes and the presence of a broadly neutralizing response, indicating that antigen presentation may be important for the production of HCV-neutralizing antibodies. H epatitis C virus (HCV) is a significant cause of liver morbidity and mortality worldwide (1). In the majority (75%) of those infected, the infection proceeds to a chronic infection (2). Symptomatic acute HCV infection is rare; therefore, HCV has the potential to spread undetected among those at risk. In countries with a high prevalence, a poor health care i...

show abstract

Variations of serum IgG subclass levels in hepatitis C virus infection during interferon-α therapy

Cited by 5 publications

References 30 publications

Biochemical evaluation of the combination of Pegylated IFN-α2b and Ribavarin therapy of Egyptian patients suffering from Hepatitis C Virus

Biochemical evaluation of the combination of Pegylated IFN-α2b and Ribavarin therapy of Egyptian patients suffering from Hepatitis C Virus

C3/Ig and Ig/C3 two-component-determined circulating immune complexes (TCIC) in patients with HCV infection

Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection

Contact Info

Product

Resources

About